GlassScriptPhysician profile
Melissa G Young
NPI 1831174739
$20,390.01
in general payments reported to CMS, 2019-2025
54 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,787 · 2020: $1,746 · 2021: $1,710 · 2022: $982 · 2023: $984 · 2024: $647 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $2,613 · Travel and Lodging: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,170.00 |
| Food and Beverage | $2,613.13 |
| Travel and Lodging | $382.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $11,655.44 | 2019-2025 | |
| Novo Nordisk INC | $1,884.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $880.76 | 2019-2025 | Jardiance, Lyumjev, Baqsimi |
| Insulet Corporation | $700.38 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $650.57 | 2019-2023 | Farxiga |
| Mannkind Corporation | $466.45 | 2019-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.46 | 2019-2025 | Jardiance |
| Dexcom, INC. | $386.80 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $251.92 | 2019-2021 | |
| Radius Health, INC. | $244.71 | 2019-2025 | Binosto, Tymlos |
| Abbott Laboratories | $229.30 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $187.03 | 2019-2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $173.53 | 2020-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $170.56 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $162.18 | 2019-2023 | Unithroid |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.